307 related articles for article (PubMed ID: 37175894)
1. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
Lopetuso LR; Cuomo C; Mignini I; Gasbarrini A; Papa A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175894
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
5. TNF inhibitors for psoriasis.
Chima M; Lebwohl M
Semin Cutan Med Surg; 2018 Sep; 37(3):134-142. PubMed ID: 30215629
[TBL] [Abstract][Full Text] [Related]
6. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
Wang Y; Wang H; Jiang J; Zhao D; Liu Y
Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication-associated injury.
Hutchings D; Miller JA; Voltaggio L
Hum Pathol; 2019 Mar; 85():202-209. PubMed ID: 30452927
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
12. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
13. Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
Hong JJ; Hadeler EK; Mosca ML; Brownstone ND; Bhutani T; Liao WJ
Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130397
[TBL] [Abstract][Full Text] [Related]
14. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
17. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
[TBL] [Abstract][Full Text] [Related]
18. Upside and Downside of Tumor Necrosis Factor Blockers for Treatment of Immune/Inflammatory Diseases.
Kunnumakkara AB; Thakur KK; Rana V; Bora B; Banik K; Khatoon E; Sailo BL; Shabnam B; Girisa S; Gupta SC; Aggarwal BB
Crit Rev Immunol; 2019; 39(6):439-479. PubMed ID: 32421957
[TBL] [Abstract][Full Text] [Related]
19. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
20. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]